Here's What This Drug News Could Mean for AbbVie's Shareholders
On May 11, AbbVie (NYSE: ABBV) announced positive top-line results in its phase 3 clinical trial of patients receiving Rinvoq to treat moderate-to-severe Crohn's disease.
What was the specific data for the clinical trial results? And what could a Rinvoq Crohn's disease indication in the U.S. add to pharma stock AbbVie's annual revenue? Let's dig in to find out.
Crohn's disease is an inflammatory bowel disease (IBD) that leads to chronic inflammation and damage to the digestive tract, similar to the other form of IBD called ulcerative colitis. But there is a key difference between the two diseases. Unlike ulcerative colitis that affects only the colon and the rectum, Crohn's disease can impact any part of the digestive tract, such as the mouth or the anus.
Source Fool.com
